EA201071045A1 - Соединения оксадиазоантрацена для лечения диабета - Google Patents

Соединения оксадиазоантрацена для лечения диабета

Info

Publication number
EA201071045A1
EA201071045A1 EA201071045A EA201071045A EA201071045A1 EA 201071045 A1 EA201071045 A1 EA 201071045A1 EA 201071045 A EA201071045 A EA 201071045A EA 201071045 A EA201071045 A EA 201071045A EA 201071045 A1 EA201071045 A1 EA 201071045A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxadiazoanthracene
diabetes
derivatives
compounds
treatment
Prior art date
Application number
EA201071045A
Other languages
English (en)
Other versions
EA018225B1 (ru
Inventor
Аднан М.М. Мджалли
Дхарма Рао Полисетти
Томас Скотт Йокум
Калпати Сантош
Мустафа Гузель
Кристофер Бем
Стефен Томас Дэвис
Original Assignee
Транстек Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Транстек Фарма, Инк. filed Critical Транстек Фарма, Инк.
Publication of EA201071045A1 publication Critical patent/EA201071045A1/ru
Publication of EA018225B1 publication Critical patent/EA018225B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Abstract

Настоящее изобретение относится к производным оксадиазоантрацена формулы (I)где А, В, С, R, R, R, R, Rи Rопределены в описании изобретения, фармацевтическим композициям, включающим производные оксадиазоантрацена, применению производных оксадиазоантрацена для получения фармацевтических композиций, способам их применения для лечения и/или предотвращения расстройств и заболеваний, таких как диабет, и промежуточным соединениям, используемым для получения производных оксадиазоантрацена формулы (I).
EA201071045A 2008-03-07 2009-03-06 Соединения оксадиазоантрацена для лечения диабета EA018225B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
PCT/US2009/036333 WO2009111700A2 (en) 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes

Publications (2)

Publication Number Publication Date
EA201071045A1 true EA201071045A1 (ru) 2011-02-28
EA018225B1 EA018225B1 (ru) 2013-06-28

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071045A EA018225B1 (ru) 2008-03-07 2009-03-06 Соединения оксадиазоантрацена для лечения диабета

Country Status (18)

Country Link
US (7) US7727983B2 (ru)
EP (1) EP2262364B1 (ru)
JP (1) JP5382952B2 (ru)
KR (1) KR101616737B1 (ru)
CN (1) CN101959405B (ru)
AU (1) AU2009221722B2 (ru)
BR (1) BRPI0910282A2 (ru)
CA (1) CA2716664C (ru)
DK (1) DK2262364T3 (ru)
EA (1) EA018225B1 (ru)
ES (1) ES2567451T3 (ru)
HK (1) HK1148435A1 (ru)
IL (1) IL207570A (ru)
MA (1) MA32175B1 (ru)
MX (1) MX2010009752A (ru)
NZ (1) NZ587343A (ru)
WO (1) WO2009111700A2 (ru)
ZA (1) ZA201006367B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959405B (zh) * 2008-03-07 2014-07-02 转化技术制药有限责任公司 治疗糖尿病的氧杂二氮杂蒽化合物
KR101732978B1 (ko) * 2009-03-30 2017-05-08 브이티브이 테라퓨틱스 엘엘씨 치환된 아조안트라센 유도체, 약제학적 조성물, 및 그것의 사용방법
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
WO2012096824A1 (en) 2011-01-12 2012-07-19 Transtech Pharma, Inc. Phenylglyoxylic acid derivatives and their preparation and use
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
CN103732578B (zh) 2011-07-22 2015-08-12 辉瑞大药厂 喹啉基胰高血糖素受体调节剂
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013142569A1 (en) * 2012-03-22 2013-09-26 Transtech Pharma, Inc. Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
EA201591123A1 (ru) * 2013-01-17 2015-11-30 виТиви ТЕРАПЬЮТИКС ЭлЭлСи Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
MX2017000972A (es) * 2014-07-25 2017-07-27 Celgene Int Ii Sarl Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
CA3090823A1 (en) 2018-05-08 2019-11-14 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4159737A1 (en) * 2020-05-28 2023-04-05 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Method for preparing glp-1 receptor agonist free base
US20230348483A1 (en) * 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
US20230322756A1 (en) 2020-09-01 2023-10-12 Jiangsu Hengrui Medicine Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
WO2022078152A1 (zh) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
WO2022111624A1 (zh) 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
EP4317142A1 (en) 2021-03-22 2024-02-07 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
EP4317145A1 (en) 2021-03-24 2024-02-07 Shionogi & Co., Ltd Pharmaceutical composition containing glp-1 receptor agonist having fused ring
CN117500808A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
CA3219984A1 (en) 2021-06-24 2022-12-29 Wenqiang ZHAI Glp-1 receptor agonist and composition and use thereof
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物
PT873295E (pt) * 1995-10-06 2003-08-29 Ligand Pharm Inc Moduladores de rxr selectivos para dimeros para a sua utilizacao
AU3033500A (en) * 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
YU50302A (sh) * 1999-12-03 2006-01-16 Kyoto Pharmaceutical Industries Ltd. Nova heterociklična jedinjenja, njihove soli i njihova primena u medicini
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US20050222036A1 (en) 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
EP1611104B1 (en) * 2003-03-26 2009-07-01 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
CN101959405B (zh) * 2008-03-07 2014-07-02 转化技术制药有限责任公司 治疗糖尿病的氧杂二氮杂蒽化合物
EP2579888A2 (en) 2010-06-09 2013-04-17 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
EP2262364A4 (en) 2012-04-04
CA2716664A1 (en) 2009-09-11
AU2009221722B2 (en) 2014-12-18
EA018225B1 (ru) 2013-06-28
ES2567451T3 (es) 2016-04-22
HK1148435A1 (en) 2011-09-09
JP5382952B2 (ja) 2014-01-08
IL207570A (en) 2014-03-31
US20110039837A1 (en) 2011-02-17
JP2011513431A (ja) 2011-04-28
CN101959405B (zh) 2014-07-02
MA32175B1 (fr) 2011-03-01
US8933222B2 (en) 2015-01-13
CA2716664C (en) 2016-10-11
US20100324033A1 (en) 2010-12-23
US8524708B2 (en) 2013-09-03
NZ587343A (en) 2012-05-25
US7727983B2 (en) 2010-06-01
EP2262364A2 (en) 2010-12-22
CN101959405A (zh) 2011-01-26
US20100197677A1 (en) 2010-08-05
US7790714B2 (en) 2010-09-07
BRPI0910282A2 (pt) 2015-09-01
WO2009111700A3 (en) 2010-03-04
US20090306063A1 (en) 2009-12-10
US20140187769A1 (en) 2014-07-03
AU2009221722A1 (en) 2009-09-11
US9120813B2 (en) 2015-09-01
EP2262364B1 (en) 2016-03-02
US20150087640A1 (en) 2015-03-26
MX2010009752A (es) 2010-09-30
KR101616737B1 (ko) 2016-05-02
DK2262364T3 (en) 2016-03-21
US7906507B2 (en) 2011-03-15
US8703766B2 (en) 2014-04-22
ZA201006367B (en) 2011-05-25
IL207570A0 (en) 2010-12-30
US20130317015A1 (en) 2013-11-28
KR20100131455A (ko) 2010-12-15
WO2009111700A2 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201001159A1 (ru) Конденсированные гетероциклические производные и их применение
EA200971074A1 (ru) Антивирусные соединения
EA201070158A1 (ru) Сульфонамиды в качестве trpm8 модуляторов
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
EA201001508A1 (ru) Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201270575A1 (ru) Соединения
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
EA201100299A1 (ru) Органические соединения
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201190259A1 (ru) Противовирусные соединения
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
MA32811B1 (fr) Nouveaux composés
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU